



## DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

### Relevant Financial Relationships

The following individuals involved in the planning, development, review, presentation, authoring and/or editing of the symposium content have disclosed relevant financial relationships with ineligible companies\*, and the CME Department has mitigated these potential conflicts of interest. \*\*Indicates that this individual's presentation **will include** discussion of off-label or unapproved usage.

- **Ahluwalia, Manmeet, M.D.**, faculty for this educational activity, is a consultant with Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Caim Therapeutics, Theraguix, Anheart Therapeutics and Varian Medical Systems. He is also a researcher for AstraZeneca, Bayer, BMS, Incyte, Merck, Mimivax, Novocure and Pharmacyclics; is a shareholder with Mimivax, Cytodyn, MedInnovate Advisors LLC; and on the scientific advisory board for Cairn Therapeutics, Pyramid Biosciences and Modifi Biosciences. Dr. Ahluwalia indicated that the presentation or discussion will include off-label or unapproved product usage.
- **De los Rios La Rosa, Felipe, M.D.**, faculty for this educational activity is a member of the speakers' bureau for AstraZeneca (Andexxa and Brilinta).
- **Gandhi, Ripal, M.D.**, faculty for this educational activity is a consultant for Boston Scientific, Medtronic, BD, Cordis, Inari, Cook Medical and Terumo. He is also a member of the speakers' bureau for Argon, Penumbra and Inari.
- **Linfante, Italo, M.D.\*\***, faculty for this activity is a consultant for Medtronic, Cerenovus, Stryker, VizAI, Penumbra and Q'Appel. Dr. Linfante is a member of the speakers' bureau for Medtronic, Cerevovus, Stryker, VizAI, Penumbra and Q'Appel. And stockholder for Deinde, InNeuroCo, InNeuroFlne, Prometheus, Bend it, Prolong Pharmaceuticals and Three Rivers.
- **Mahtani, Reshma, D.O.**, faculty for this educational activity is a consultant for Agendia, Amgen, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Novartis, Pfizer, Puma, Sanofi, Stemline, and Sermonix.
- **McDermott, Michael, M.D.**, moderator for this activity is a consultant for Diende, Stryker, Insightech, Light Helmet, and OsteoMed.
- **Odia, Yazmin, M.D.\*\***, faculty for this activity has received grant/ research support from Bristol Myers Squibb, Novocure, Chimerix, Karyopharm, VBI Therapeutics, MIMIVAX, and CNS Pharmaceuticals. She is a consultant for Pharpoint Research and an advisor for Actuate Therapeutics, Oncoceutics Bod, DSMB Gamma Tile.
- **Ouellete, Elizabeth Ann, M.D.\*\***, faculty for this activity is an advisor for Integra.
- **Uribe, John M.D.**, faculty for this activity receives royalties from ConMed and owns stocks for ArthroSurface.
- **Villa, Alessandro, DDS, Ph.D., MPH\*\***, faculty for this activity has received grant/ research support from Mairagtx, Merck, Mureva. He is a consultant for Afyx Therapeutics, Lipella Pharmaceuticals and K Pharm. He receives royalties from UpToDate.

These relationships have been mitigated.

### Nothing to Disclose

The following individuals do not have relevant financial relationships with ineligible companies\*. \*\*Indicates that this individual's presentation will include discussion of off-label or unapproved usage.

- Jimenez, Javier, M.D.
- Kalman, Noah, M.D.
- Kaiser, Adeel, M.D.
- Lipkin, Scott, DPM
- Papagni, Paul J.D.
- Paralicci, Giovanni, M.D.
- Zinner, Michael, M.D.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies\* to disclose.

\*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.